866-997-4948(US-Canada Toll Free)

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 64 Pages

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2016, provides in depth analysis on RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Overview 7
Therapeutics Development 8
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Stage of Development 8
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Therapy Area 9
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Indication 10
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Companies 13
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Products under Development by Universities/Institutes 15
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 23
Amitech Therapeutic Solutions, Inc. 23
Basilea Pharmaceutica Ltd 24
CBT Pharmaceuticals Inc 25
Chugai Pharmaceutical Co Ltd 26
Hanmi Pharmaceuticals Co Ltd 27
Millennium Pharmaceuticals Inc 28
Novartis AG 29
Redx Pharma Plc 30
Sirnaomics Inc 31
VG Life Sciences Inc 32
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles 33
BAL-3833 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CBT-102 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
DCBCI-0902 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
FYA-1001 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
HM-95573 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
hydroxychloroquine + sorafenib tosylate - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
LXH-254 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
RG-7304 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules to Inhibit Raf Kinases for Oncology - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
STP-503 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
TAK-580 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
TEW-0201 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Projects 51
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products 52
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Featured News & Press Releases 53
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug HM95573 at ASCO 53
Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting 53
Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting 54
Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent 54
Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment 55
Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study 55
Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study 56
Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study 57
Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association; 58
Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study 59
Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine 59
Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib 60
Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer 60
Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors 62
Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Amitech Therapeutic Solutions, Inc., H2 2016 23
Pipeline by Basilea Pharmaceutica Ltd, H2 2016 24
Pipeline by CBT Pharmaceuticals Inc, H2 2016 25
Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 26
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 27
Pipeline by Millennium Pharmaceuticals Inc, H2 2016 28
Pipeline by Novartis AG, H2 2016 29
Pipeline by Redx Pharma Plc, H2 2016 30
Pipeline by Sirnaomics Inc, H2 2016 31
Pipeline by VG Life Sciences Inc, H2 2016 32
Dormant Projects, H2 2016 51
Discontinued Products, H2 2016 52

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *